透過您的圖書館登入
IP:3.137.192.3
  • 學位論文

液化澱粉芽孢桿菌菌粉對高脂飲食誘導倉鼠血脂異常之影響

The effects of Bacillus amyloliquefaciens powder on high-fat diet-induced dyslipidemia in hamsters

指導教授 : 陳與國
若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


高脂血症被認為是造成心血管疾病的危險因素,其是指血液中的總膽固醇 (Total cholesterol, TC)、三酸甘油酯 (Triglyceride, TG)、低密度脂蛋白膽固醇 (Low-density lipoprotein cholesterol, LDL-C) 含量升高,而高密度脂蛋白膽固醇 (High-density lipoprotein cholesterol, HDL-C) 含量降低,進一步會促使動脈粥狀硬化斑塊形成,故藉由調節血脂可有效降低心血管疾病的發生率。本實驗使用液化澱粉芽孢桿菌菌粉 (Bacillus amyloliquefaciens powder, BAP) 作為樣品,以四週齡的雄性敘利亞倉鼠作為實驗動物,探討液化澱粉芽孢桿菌菌粉對高脂飲食誘導倉鼠血脂異常之影響,分為以下五組:(1) 控制組 (C)、(2) 高脂高膽固醇組 (HFD)、(3) 低劑量液化澱粉芽孢桿菌菌粉組 (HFD+管餵25 mg/kg/day BAP, 1×)、(4) 中劑量液化澱粉芽孢桿菌菌粉組 (HFD+管餵50 mg/kg/day BAP, 2×)、(5) 高劑量液化澱粉芽孢桿菌菌粉組 (HFD+管餵125 mg/kg/day BAP, 5×)。根據實驗結果顯示,給予倉鼠六週高脂飲食後,HFD組血液及肝臟中的TG及TC濃度皆高於C組,而HFD組的脂肪組織重量也明顯高於C組,給予BAP的組別能降低體內中的TG、TC及LDL-C,並使HDL-C上升,並能增加糞便中TG及TC的排出,降低肝臟中的TG濃度。經西方墨點法結果顯示,BAP的給予藉由活化磷酸化的5'-AMP-activated protein kinase (AMPK),從而降低sterol regulatory element binding protein 2 (SREBP2)及hydroxymethylglutaryl-CoA reductase (HMGCR) 蛋白的表現量來抑制膽固醇的合成,以及增加LDL receptor (LDLR)、liver X receptor α (LXR-α) 及peroxisome proliferator-activated receptor α (PPAR-α) 蛋白的表現促進膽固醇的排泄。綜合以上所述,BAP可有效調節血脂,並且具有防止動脈粥狀硬化斑塊形成之潛力。

並列摘要


Hyperlipidemia is considered to be a risk factor for cardiovascular disease, and it refers to elevated blood levels of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (low-density lipoprotein) and decreased content of high-density lipoprotein cholesterol (HDL-C). Therefore, regulating blood lipids can effectively reduce the incidence of atherosclerosis and cardiovascular diseases. In this experiment, Bacillus amyloliquefaciens powder (BAP) was used as a sample, and four-week-old male Syrian hamsters were used as experimental animals to evlauate the effects of Bacillus amyloliquefaciens powder on blood lipid disorders in hamsters induced by high-fat diet. The hamsters were divided into the following five groups: (1) control group (C), (2) high-fat and high-cholesterol group (HFD), (3) low-dose Bacillus amyloliquefaciens powder group (HFD+ 25 mg/kg/day BAP, 1×), (4) medium-dose Bacillus amyloliquefaciens powder group (HFD+ 50mg/kg/day BAP, 2×), (5) high-dose Bacillus amyloliquefaciens powder group (HFD+ 125 mg/kg/day BAP, 5×). According to the experimental results, after giving hamsters a high-fat/high-cholesterol diet for six weeks, the TG and TC levels of serum and liver in hamsters of the HFD group were higher than those of the C group, and the tissue weight of the HFD group was also significantly higher than that of the C group. The treatment of BAP reduced serum levels of TG, TC and LDL-C, and increased HDL-C levels. BAP also increased the excretion of TG and TC in feces and reduced the concent of TG in the liver. The results of western blot showed that BAP adiminstration reduced protein expression of sterol regulatory element binding protein 2 (SREBP2) and hydroxymethylglutaryl-CoA reductase (HMGCR) via activating phosphorylated 5'- AMP-activated protein kinase (AMPK) to inhibit cholesterol synthesis of liver, and increased LDL receptor (LDLR), liver X receptor α (LXR-α) and peroxisome proliferator-activated receptor α (PPAR-α) proteins to promote the excretion of cholesterol. In summary, BAP can effectively regulate blood lipids and has the potential to prevent the formation of atherosclerotic plaques.

參考文獻


行政院衛生福利部。2021。中華民國109年國人主要死因統計資料。
An, H. J., J. Y. Kim, G. M. Gyeong, G. Hyemin, H. J. Kim, J. Leem, S. W. Youn, and K. K. Park. 2020. Beneficial effects of SREBP decoy oligodeoxynucleotide in an animal model of hyperlipidemia. Int. J. Mol. Sci. 21(2): 552.
Aminlari, L., S. S. Shekarforoush, S. Hosseinzadeh, S. Nazifi, J. Sajedianfard, and H. M. Eskandari. 2019. Effect of probiotics Bacillus coagulans and Lactobacillus plantarum on lipid profile and feces bacteria of rats fed cholesterol-enriched diet. Probiotics Antimicrob. Proteins. 11: 1163-1171.
Aly, F. Z., and D. E. Kleiner. 2011. Update on fatty liver disease and steatohepatitis. Adv Anat Pathol. 18(4): 294-300.
Begley, M., C. Hill, and C. G. Gahan. 2006. Bile salt hydrolase activity in probiotics. Appl. Environ. Microbiol. 72(3): 1729-1738.

延伸閱讀